Investigating liver cancer disparities in Alaska Native and American Indian populations
Liver Cancer Disparities in Alaska Native and American Indian People
This study is looking into why liver cancer is more common and deadly for Alaska Native and American Indian people, and it wants to find out what specific risks, like hepatitis and alcohol use, might be causing this, so we can help improve health and support early detection for those communities.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10706310 on NIH RePORTER |
What this research studies
This research focuses on understanding the rising rates of liver cancer among Alaska Native and American Indian people, who experience significantly higher incidence and mortality rates compared to other populations. The study aims to identify unique risk factors, such as viral hepatitis, alcohol use disorders, and environmental pollutants, that contribute to these disparities. By emphasizing early detection and tailored management strategies, the research seeks to improve health outcomes for these communities. Patients may be involved in discussions about their health and the factors affecting liver cancer risk.
Who could benefit from this research
Good fit: Ideal candidates for this research include Alaska Native and American Indian individuals at risk for liver cancer due to factors like hepatitis infection, alcohol use disorders, or obesity.
Not a fit: Patients who do not belong to Alaska Native or American Indian populations may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved early detection and treatment strategies for liver cancer in Alaska Native and American Indian populations.
How similar studies have performed: Previous research has highlighted health disparities in cancer outcomes among minority populations, suggesting that targeted approaches can lead to meaningful improvements.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Ioannou, George — University of Washington
- Study coordinator: Ioannou, George
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.